Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants

Bibliographic Details
Main Author: Kislaya, Irina
Publication Date: 2023
Other Authors: Peralta-Santos, André, Borges, Vítor, Vieira, Luís, Sousa, Carlos, Ferreira, Bibiana, Pelerito, Ana, Gomes, João Paulo, Leite, Pedro Pinto, Nunes, Baltazar, PT COVID-19 group, Machado, Ausenda, Rodrigues, Ana Paula, Peixoto, Vasco Ricoca, Casaca, Pedro, Fernandes, Eugenia, Rodrigues, Eduardo, Ferreira, Rita, Isidro, Joana, Pinto, Miguel, Duarte, Sílvia, Santos, Daniela, Meneses, Luís, Almeida, José Pedro, Matias, Ana, Freire, Samanta, Grilo, Teresa
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/155613
Summary: Funding Information: The acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776), supported by the European Commission through the European Centre for Disease Control, and also partially funded by the Genome PT project (grant no. POCI‐01‐0145‐FEDER‐022184), supported by COMPETE 2020–Operational Programme for Competitiveness and Internationalisation, Lisboa Portugal Regional Operational Programme, Algarve Portugal Regional Operational, under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund, and by the Portuguese Science and Technology Foundation. The Algarve Biomedical Center Laboratory received public funding through the Project ALG‐D2‐2021‐06 Variants Screen in Southern Portugal–Monitoring Variants of Concern in Southern Portugal and the Portuguese Science and Technology Foundation national support through the Comprehensive Health Research Center (grant no. UIDP/04923/2020). Funding information Funding Information: The acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776), supported by the European Commission through the European Centre for Disease Control, and also partially funded by the Genome PT project (grant no. POCI-01-0145-FEDER-022184), supported by COMPETE 2020–Operational Programme for Competitiveness and Internationalisation, Lisboa Portugal Regional Operational Programme, Algarve Portugal Regional Operational, under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund, and by the Portuguese Science and Technology Foundation. The Algarve Biomedical Center Laboratory received public funding through the Project ALG-D2-2021-06 Variants Screen in Southern Portugal–Monitoring Variants of Concern in Southern Portugal and the Portuguese Science and Technology Foundation national support through the Comprehensive Health Research Center (grant no. UIDP/04923/2020). Publisher Copyright: © 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
id RCAP_68bee7af2d0c4ce0ee22c91108775b30
oai_identifier_str oai:run.unl.pt:10362/155613
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variantsa case–case study based on electronic health recordscase–case designCOVID-19Delta variantOmicron variantSARS-CoV-2vaccine effectivenessEpidemiologyPulmonary and Respiratory MedicinePublic Health, Environmental and Occupational HealthInfectious DiseasesSDG 3 - Good Health and Well-beingFunding Information: The acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776), supported by the European Commission through the European Centre for Disease Control, and also partially funded by the Genome PT project (grant no. POCI‐01‐0145‐FEDER‐022184), supported by COMPETE 2020–Operational Programme for Competitiveness and Internationalisation, Lisboa Portugal Regional Operational Programme, Algarve Portugal Regional Operational, under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund, and by the Portuguese Science and Technology Foundation. The Algarve Biomedical Center Laboratory received public funding through the Project ALG‐D2‐2021‐06 Variants Screen in Southern Portugal–Monitoring Variants of Concern in Southern Portugal and the Portuguese Science and Technology Foundation national support through the Comprehensive Health Research Center (grant no. UIDP/04923/2020). Funding information Funding Information: The acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776), supported by the European Commission through the European Centre for Disease Control, and also partially funded by the Genome PT project (grant no. POCI-01-0145-FEDER-022184), supported by COMPETE 2020–Operational Programme for Competitiveness and Internationalisation, Lisboa Portugal Regional Operational Programme, Algarve Portugal Regional Operational, under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund, and by the Portuguese Science and Technology Foundation. The Algarve Biomedical Center Laboratory received public funding through the Project ALG-D2-2021-06 Variants Screen in Southern Portugal–Monitoring Variants of Concern in Southern Portugal and the Portuguese Science and Technology Foundation national support through the Comprehensive Health Research Center (grant no. UIDP/04923/2020). Publisher Copyright: © 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.Background: Information on vaccine effectiveness in a context of novel variants of concern (VOC) emergence is of key importance to inform public health policies. This study aimed to estimate a measure of comparative vaccine effectiveness between Omicron (BA.1) and Delta (B.1.617.2 and sub-lineages) VOC according to vaccination exposure (primary or booster). Methods: We developed a case–case study using data on RT-PCR SARS-CoV-2-positive cases notified in Portugal during Weeks 49–51, 2021. To obtain measure of comparative vaccine effectiveness, we compared the odds of vaccination in Omicron cases versus Delta using logistic regression adjusted for age group, sex, region, week of diagnosis, and laboratory of origin. Results: Higher odds of vaccination were observed in cases infected by Omicron VOC compared with Delta VOC cases for both complete primary vaccination (odds ratio [OR] = 2.1; 95% confidence interval [CI]: 1.8 to 2.4) and booster dose (OR = 5.2; 95% CI: 3.1 to 8.8), equivalent to reduction of vaccine effectiveness from 44.7% and 92.8%, observed against infection with Delta, to −6.0% (95% CI: 29.2% to 12.7%) and 62.7% (95% CI: 35.7% to 77.9%), observed against infection with Omicron, for complete primary vaccination and booster dose, respectively. Conclusion: Consistent reduction in vaccine-induced protection against infection with Omicron was observed. Complete primary vaccination may not be protective against SARS-CoV-2 infection in regions where Omicron variant is dominant.Comprehensive Health Research Centre (CHRC) - Pólo ENSPCentro de Investigação em Saúde Pública (CISP/PHRC)Escola Nacional de Saúde Pública (ENSP)RUNKislaya, IrinaPeralta-Santos, AndréBorges, VítorVieira, LuísSousa, CarlosFerreira, BibianaPelerito, AnaGomes, João PauloLeite, Pedro PintoNunes, BaltazarPT COVID-19 groupMachado, AusendaRodrigues, Ana PaulaPeixoto, Vasco RicocaCasaca, PedroFernandes, EugeniaRodrigues, EduardoFerreira, RitaIsidro, JoanaPinto, MiguelDuarte, SílviaSantos, DanielaMeneses, LuísAlmeida, José PedroMatias, AnaFreire, SamantaGrilo, Teresa2023-07-20T22:15:40Z2023-032023-03-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/155613eng1750-2640PURE: 66657635https://doi.org/10.1111/irv.13121info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-10-21T01:36:47Zoai:run.unl.pt:10362/155613Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:43:45.754052Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
a case–case study based on electronic health records
title Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
spellingShingle Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
Kislaya, Irina
case–case design
COVID-19
Delta variant
Omicron variant
SARS-CoV-2
vaccine effectiveness
Epidemiology
Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health
Infectious Diseases
SDG 3 - Good Health and Well-being
title_short Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
title_full Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
title_fullStr Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
title_full_unstemmed Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
title_sort Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
author Kislaya, Irina
author_facet Kislaya, Irina
Peralta-Santos, André
Borges, Vítor
Vieira, Luís
Sousa, Carlos
Ferreira, Bibiana
Pelerito, Ana
Gomes, João Paulo
Leite, Pedro Pinto
Nunes, Baltazar
PT COVID-19 group
Machado, Ausenda
Rodrigues, Ana Paula
Peixoto, Vasco Ricoca
Casaca, Pedro
Fernandes, Eugenia
Rodrigues, Eduardo
Ferreira, Rita
Isidro, Joana
Pinto, Miguel
Duarte, Sílvia
Santos, Daniela
Meneses, Luís
Almeida, José Pedro
Matias, Ana
Freire, Samanta
Grilo, Teresa
author_role author
author2 Peralta-Santos, André
Borges, Vítor
Vieira, Luís
Sousa, Carlos
Ferreira, Bibiana
Pelerito, Ana
Gomes, João Paulo
Leite, Pedro Pinto
Nunes, Baltazar
PT COVID-19 group
Machado, Ausenda
Rodrigues, Ana Paula
Peixoto, Vasco Ricoca
Casaca, Pedro
Fernandes, Eugenia
Rodrigues, Eduardo
Ferreira, Rita
Isidro, Joana
Pinto, Miguel
Duarte, Sílvia
Santos, Daniela
Meneses, Luís
Almeida, José Pedro
Matias, Ana
Freire, Samanta
Grilo, Teresa
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Comprehensive Health Research Centre (CHRC) - Pólo ENSP
Centro de Investigação em Saúde Pública (CISP/PHRC)
Escola Nacional de Saúde Pública (ENSP)
RUN
dc.contributor.author.fl_str_mv Kislaya, Irina
Peralta-Santos, André
Borges, Vítor
Vieira, Luís
Sousa, Carlos
Ferreira, Bibiana
Pelerito, Ana
Gomes, João Paulo
Leite, Pedro Pinto
Nunes, Baltazar
PT COVID-19 group
Machado, Ausenda
Rodrigues, Ana Paula
Peixoto, Vasco Ricoca
Casaca, Pedro
Fernandes, Eugenia
Rodrigues, Eduardo
Ferreira, Rita
Isidro, Joana
Pinto, Miguel
Duarte, Sílvia
Santos, Daniela
Meneses, Luís
Almeida, José Pedro
Matias, Ana
Freire, Samanta
Grilo, Teresa
dc.subject.por.fl_str_mv case–case design
COVID-19
Delta variant
Omicron variant
SARS-CoV-2
vaccine effectiveness
Epidemiology
Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health
Infectious Diseases
SDG 3 - Good Health and Well-being
topic case–case design
COVID-19
Delta variant
Omicron variant
SARS-CoV-2
vaccine effectiveness
Epidemiology
Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health
Infectious Diseases
SDG 3 - Good Health and Well-being
description Funding Information: The acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776), supported by the European Commission through the European Centre for Disease Control, and also partially funded by the Genome PT project (grant no. POCI‐01‐0145‐FEDER‐022184), supported by COMPETE 2020–Operational Programme for Competitiveness and Internationalisation, Lisboa Portugal Regional Operational Programme, Algarve Portugal Regional Operational, under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund, and by the Portuguese Science and Technology Foundation. The Algarve Biomedical Center Laboratory received public funding through the Project ALG‐D2‐2021‐06 Variants Screen in Southern Portugal–Monitoring Variants of Concern in Southern Portugal and the Portuguese Science and Technology Foundation national support through the Comprehensive Health Research Center (grant no. UIDP/04923/2020). Funding information Funding Information: The acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776), supported by the European Commission through the European Centre for Disease Control, and also partially funded by the Genome PT project (grant no. POCI-01-0145-FEDER-022184), supported by COMPETE 2020–Operational Programme for Competitiveness and Internationalisation, Lisboa Portugal Regional Operational Programme, Algarve Portugal Regional Operational, under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund, and by the Portuguese Science and Technology Foundation. The Algarve Biomedical Center Laboratory received public funding through the Project ALG-D2-2021-06 Variants Screen in Southern Portugal–Monitoring Variants of Concern in Southern Portugal and the Portuguese Science and Technology Foundation national support through the Comprehensive Health Research Center (grant no. UIDP/04923/2020). Publisher Copyright: © 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
publishDate 2023
dc.date.none.fl_str_mv 2023-07-20T22:15:40Z
2023-03
2023-03-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/155613
url http://hdl.handle.net/10362/155613
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1750-2640
PURE: 66657635
https://doi.org/10.1111/irv.13121
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596920216420352